Insulin-producing organoids engineered from islet and amniotic epithelial cells to treat diabetes

Fanny Lebreton; Vanessa Lavallard; Kevin Bellofatto; Romain Bonnet; Charles H. Wassmer; Lisa Perez; Vakhtang Kalandadze; Antonia Follenzi; Michel Boulvain; Julie Kerr-Conte; David J. Goodman; Domenico Bosco; Thierry Berney; Ekaterine Berishvili

doi:10.1038/s41467-019-12472-3

Insulin-producing organoids engineered from islet and amniotic epithelial cells to treat diabetes

Fanny Lebreton, Vanessa Lavallard, Kevin Bellofatto, Romain Bonnet, Charles H. Wassmer, Lisa Perez, Vakhtang Kalandadze, Antonia Follenzi, Michel Boulvain, Julie Kerr-Conte, David J. Goodman, Domenico Bosco, Thierry Berney, Ekaterine Berishvili

Dipartimento di Scienze della Salute

Risultato della ricerca: Contributo su rivista › Articolo in rivista › peer review

Abstract

Maintaining long-term euglycemia after intraportal islet transplantation is hampered by the considerable islet loss in the peri-transplant period attributed to inflammation, ischemia and poor angiogenesis. Here, we show that viable and functional islet organoids can be successfully generated from dissociated islet cells (ICs) and human amniotic epithelial cells (hAECs). Incorporation of hAECs into islet organoids markedly enhances engraftment, viability and graft function in a mouse type 1 diabetes model. Our results demonstrate that the integration of hAECs into islet cell organoids has great potential in the development of cell-based therapies for type 1 diabetes. Engineering of functional mini-organs using this strategy will allow the exploration of more favorable implantation sites, and can be expanded to unlimited (stem-cell-derived or xenogeneic) sources of insulin-producing cells.

Lingua originale	Inglese
Numero di articolo	4491
Rivista	Nature Communications
Volume	10
Numero di pubblicazione	1
DOI	https://doi.org/10.1038/s41467-019-12472-3
Stato di pubblicazione	Pubblicato - 1 dic 2019

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1038/s41467-019-12472-3

Altri file e collegamenti

Link to publication in Scopus

Cita questo

Lebreton, F., Lavallard, V., Bellofatto, K., Bonnet, R., Wassmer, C. H., Perez, L., Kalandadze, V., Follenzi, A., Boulvain, M., Kerr-Conte, J., Goodman, D. J., Bosco, D., Berney, T., & Berishvili, E. (2019). Insulin-producing organoids engineered from islet and amniotic epithelial cells to treat diabetes. Nature Communications, 10(1), Articolo 4491. https://doi.org/10.1038/s41467-019-12472-3

@article{02e39baa64aa41da91c341f8d22e3378,

title = "Insulin-producing organoids engineered from islet and amniotic epithelial cells to treat diabetes",

abstract = "Maintaining long-term euglycemia after intraportal islet transplantation is hampered by the considerable islet loss in the peri-transplant period attributed to inflammation, ischemia and poor angiogenesis. Here, we show that viable and functional islet organoids can be successfully generated from dissociated islet cells (ICs) and human amniotic epithelial cells (hAECs). Incorporation of hAECs into islet organoids markedly enhances engraftment, viability and graft function in a mouse type 1 diabetes model. Our results demonstrate that the integration of hAECs into islet cell organoids has great potential in the development of cell-based therapies for type 1 diabetes. Engineering of functional mini-organs using this strategy will allow the exploration of more favorable implantation sites, and can be expanded to unlimited (stem-cell-derived or xenogeneic) sources of insulin-producing cells.",

author = "Fanny Lebreton and Vanessa Lavallard and Kevin Bellofatto and Romain Bonnet and Wassmer, \{Charles H.\} and Lisa Perez and Vakhtang Kalandadze and Antonia Follenzi and Michel Boulvain and Julie Kerr-Conte and Goodman, \{David J.\} and Domenico Bosco and Thierry Berney and Ekaterine Berishvili",

note = "Publisher Copyright: {\textcopyright} 2019, The Author(s).",

year = "2019",

month = dec,

day = "1",

doi = "10.1038/s41467-019-12472-3",

language = "English",

volume = "10",

journal = "Nature Communications",

issn = "2041-1723",

publisher = "Nature Publishing Group",

number = "1",

}

Lebreton, F, Lavallard, V, Bellofatto, K, Bonnet, R, Wassmer, CH, Perez, L, Kalandadze, V, Follenzi, A, Boulvain, M, Kerr-Conte, J, Goodman, DJ, Bosco, D, Berney, T & Berishvili, E 2019, 'Insulin-producing organoids engineered from islet and amniotic epithelial cells to treat diabetes', Nature Communications, vol. 10, n. 1, 4491. https://doi.org/10.1038/s41467-019-12472-3

TY - JOUR

T1 - Insulin-producing organoids engineered from islet and amniotic epithelial cells to treat diabetes

AU - Lebreton, Fanny

AU - Lavallard, Vanessa

AU - Bellofatto, Kevin

AU - Bonnet, Romain

AU - Wassmer, Charles H.

AU - Perez, Lisa

AU - Kalandadze, Vakhtang

AU - Follenzi, Antonia

AU - Boulvain, Michel

AU - Kerr-Conte, Julie

AU - Goodman, David J.

AU - Bosco, Domenico

AU - Berney, Thierry

AU - Berishvili, Ekaterine

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Maintaining long-term euglycemia after intraportal islet transplantation is hampered by the considerable islet loss in the peri-transplant period attributed to inflammation, ischemia and poor angiogenesis. Here, we show that viable and functional islet organoids can be successfully generated from dissociated islet cells (ICs) and human amniotic epithelial cells (hAECs). Incorporation of hAECs into islet organoids markedly enhances engraftment, viability and graft function in a mouse type 1 diabetes model. Our results demonstrate that the integration of hAECs into islet cell organoids has great potential in the development of cell-based therapies for type 1 diabetes. Engineering of functional mini-organs using this strategy will allow the exploration of more favorable implantation sites, and can be expanded to unlimited (stem-cell-derived or xenogeneic) sources of insulin-producing cells.

AB - Maintaining long-term euglycemia after intraportal islet transplantation is hampered by the considerable islet loss in the peri-transplant period attributed to inflammation, ischemia and poor angiogenesis. Here, we show that viable and functional islet organoids can be successfully generated from dissociated islet cells (ICs) and human amniotic epithelial cells (hAECs). Incorporation of hAECs into islet organoids markedly enhances engraftment, viability and graft function in a mouse type 1 diabetes model. Our results demonstrate that the integration of hAECs into islet cell organoids has great potential in the development of cell-based therapies for type 1 diabetes. Engineering of functional mini-organs using this strategy will allow the exploration of more favorable implantation sites, and can be expanded to unlimited (stem-cell-derived or xenogeneic) sources of insulin-producing cells.

UR - https://www.scopus.com/pages/publications/85072942228

U2 - 10.1038/s41467-019-12472-3

DO - 10.1038/s41467-019-12472-3

M3 - Article

SN - 2041-1723

VL - 10

JO - Nature Communications

JF - Nature Communications

IS - 1

M1 - 4491

ER -

Insulin-producing organoids engineered from islet and amniotic epithelial cells to treat diabetes

Abstract

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo